EE04223B1 - Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid - Google Patents
Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeidInfo
- Publication number
- EE04223B1 EE04223B1 EEP199900313A EE9900313A EE04223B1 EE 04223 B1 EE04223 B1 EE 04223B1 EE P199900313 A EEP199900313 A EE P199900313A EE 9900313 A EE9900313 A EE 9900313A EE 04223 B1 EE04223 B1 EE 04223B1
- Authority
- EE
- Estonia
- Prior art keywords
- interferon
- liquid
- amino acids
- liquid formulation
- formulation containing
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title abstract 4
- 108010050904 Interferons Proteins 0.000 title abstract 4
- 229940079322 interferon Drugs 0.000 title abstract 4
- 150000001413 amino acids Chemical class 0.000 title abstract 3
- 239000012669 liquid formulation Substances 0.000 title 1
- 239000007788 liquid Substances 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 102000003996 Interferon-beta Human genes 0.000 abstract 2
- 108090000467 Interferon-beta Proteins 0.000 abstract 2
- 229960001388 interferon-beta Drugs 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3435396P | 1996-12-24 | 1996-12-24 | |
| PCT/US1997/023817 WO1998028007A1 (en) | 1996-12-24 | 1997-12-23 | Stable liquid interferon formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EE9900313A EE9900313A (et) | 2000-04-17 |
| EE04223B1 true EE04223B1 (et) | 2004-02-16 |
Family
ID=21875893
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP199900313A EE04223B1 (et) | 1996-12-24 | 1997-12-23 | Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid |
| EEP200300127A EE04266B1 (et) | 1996-12-24 | 1997-12-23 | Interferooni stabiilne vedelkompositsioon |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200300127A EE04266B1 (et) | 1996-12-24 | 1997-12-23 | Interferooni stabiilne vedelkompositsioon |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP0948358B2 (cs) |
| JP (5) | JP4878664B2 (cs) |
| KR (2) | KR20000069664A (cs) |
| CN (2) | CN1222315C (cs) |
| AT (1) | ATE270899T1 (cs) |
| AU (1) | AU738362B2 (cs) |
| BG (2) | BG65171B1 (cs) |
| BR (1) | BR9714434A (cs) |
| CA (1) | CA2275890C (cs) |
| CZ (1) | CZ300636B6 (cs) |
| DE (1) | DE69729880T3 (cs) |
| DK (1) | DK0948358T4 (cs) |
| EA (1) | EA002754B1 (cs) |
| EE (2) | EE04223B1 (cs) |
| ES (1) | ES2224290T5 (cs) |
| HU (1) | HU224222B1 (cs) |
| IL (1) | IL130524A (cs) |
| IS (1) | IS2070B (cs) |
| MX (1) | MX337876B (cs) |
| NO (1) | NO327844B1 (cs) |
| NZ (2) | NZ336548A (cs) |
| PL (1) | PL193447B1 (cs) |
| PT (1) | PT948358E (cs) |
| SI (1) | SI0948358T2 (cs) |
| SK (1) | SK284989B6 (cs) |
| TR (1) | TR199901968T2 (cs) |
| WO (1) | WO1998028007A1 (cs) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1222315C (zh) * | 1996-12-24 | 2005-10-12 | 拜奥根有限公司 | 稳定的液体干扰素制剂 |
| US20030190307A1 (en) | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
| CA2304808C (en) * | 1997-09-23 | 2011-03-22 | Michael Tschope | Liquid interferon-.beta. formulations |
| HK1044471A1 (en) * | 1999-05-31 | 2002-10-25 | Mitsubishi Chemical Corporation | Freeze dried hgf preparations |
| US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| UY27373A1 (es) * | 2001-07-09 | 2003-02-28 | Schering Ag | Formulaciones de interferón beta-humano |
| JP2005530683A (ja) | 2001-12-21 | 2005-10-13 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 第ｖｉｉ因子ポリペプチドの液体組成物 |
| EP1475098B1 (en) * | 2002-01-18 | 2015-08-05 | Asahi Kasei Pharma Corporation | High-concentration preparation of soluble thrombomodulin |
| KR20050013148A (ko) | 2002-06-21 | 2005-02-02 | 노보 노르디스크 에이/에스 | 인자 ⅶ 폴리펩티드의 안정화된 고체 조성물 |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7897734B2 (en) | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
| TWI272948B (en) | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
| AR044302A1 (es) * | 2003-05-13 | 2005-09-07 | Ares Trading Sa | Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos |
| WO2004103398A1 (en) | 2003-05-23 | 2004-12-02 | Novo Nordisk Health Care Ag | Protein stabilization in solution |
| CN1318087C (zh) * | 2003-06-06 | 2007-05-30 | 北京三诺佳邑生物技术有限责任公司 | 去白蛋白神经生长因子制剂 |
| KR20120104619A (ko) | 2003-08-14 | 2012-09-21 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물 |
| MXPA06005510A (es) * | 2003-11-13 | 2006-12-14 | Johnson & Johnson | Composicion y aparato para distribucion transdermica. |
| EP1532983A1 (en) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| MXPA06006886A (es) | 2003-12-19 | 2006-09-04 | Novo Nordisk Healthcare Ag | Composiciones estabilizadas de polipeptidos del factor vii. |
| ES2381674T3 (es) * | 2004-06-01 | 2012-05-30 | Ares Trading S.A. | Método de estabilizar proteínas |
| US20080193997A1 (en) * | 2004-08-24 | 2008-08-14 | Kenji Kangawa | Liquid Preparation of Physiologically Active Peptide |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| WO2006053134A2 (en) * | 2004-11-10 | 2006-05-18 | Novartis Vaccines And Diagnostics Inc. | Deamidated interferon-beta |
| EP1845925B1 (en) * | 2005-01-12 | 2016-08-24 | Biogen MA Inc. | Method for delivering interferon-beta |
| JP2008528509A (ja) * | 2005-01-21 | 2008-07-31 | アルザ コーポレイション | 少なくとも１つの対イオンを含む、向上した安定性でマイクロニードルをコーティングするための治療用ペプチド製剤 |
| EP2264161A1 (en) | 2005-07-02 | 2010-12-22 | Arecor Limited | Stable aqueous systems comprising proteins |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| CN103951667A (zh) | 2006-05-04 | 2014-07-30 | 勃林格殷格翰国际有限公司 | 多晶型 |
| CA3123813A1 (en) * | 2007-12-04 | 2009-06-11 | Biogen Chesapeake Llc | Improved glibenclamide formulations and methods for lyophilization thereof and lyophilates provided thereby |
| PL2234645T3 (pl) | 2007-12-20 | 2012-10-31 | Merck Serono Sa | Preparaty interferonu-beta modyfikowanego PEG |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| CA2726824A1 (en) | 2008-05-01 | 2009-11-05 | Arecor Limited | Protein formulation |
| EP2328607A1 (en) | 2008-07-16 | 2011-06-08 | Arecor Limited | Stable formulation of a therapeutic protein |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| CA2736421A1 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| DE102008051574A1 (de) | 2008-10-14 | 2010-04-15 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zur Herstellung von Interferon-beta und deren Varianten |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| CA2745037C (en) | 2008-12-23 | 2020-06-23 | Boehringer Ingelheim International Gmbh | Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| DE102009032179A1 (de) | 2009-07-07 | 2011-01-13 | Biogenerix Ag | Verfahren zur Reinigung von Interferon beta |
| EA034869B1 (ru) | 2009-11-27 | 2020-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин |
| TR201903403T4 (tr) | 2010-02-04 | 2019-04-22 | Csl Behring Ag | İmmünoglobulin preparatı. |
| EP2361636A1 (en) | 2010-02-26 | 2011-08-31 | CSL Behring AG | Immunoglobulin preparation and storage system for an immunoglobulin preparation |
| DE102010011430A1 (de) * | 2010-03-15 | 2011-09-15 | Kurt Koch | Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung |
| CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| ES2802243T3 (es) | 2010-06-24 | 2021-01-18 | Boehringer Ingelheim Int | Terapia para la diabetes |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| JP5538568B2 (ja) * | 2010-12-09 | 2014-07-02 | 丸石製薬株式会社 | アセトアミノフェンの安定化剤 |
| DK2686002T3 (en) * | 2011-03-15 | 2018-04-30 | Biogen Ma Inc | PROCEDURE FOR REDUCING INFLUENZA-SIMILAR SYMPTOMS CONNECTED WITH INTRAMUSCULAR ADMINISTRATION OF INTERFERON USING AN INCREASING TITRATION DOSAGE REGULATION |
| MX366629B (es) | 2011-07-15 | 2019-07-17 | Boehringer Ingelheim Int | Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas. |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| CA2864740A1 (en) * | 2012-04-19 | 2013-10-24 | C.R. Bard, Inc. | Infusates with enhanced ph stability under ethylene oxide sterilization |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| ES2929025T3 (es) | 2012-05-14 | 2022-11-24 | Boehringer Ingelheim Int | Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| ITMI20120913A1 (it) * | 2012-05-28 | 2013-11-29 | Nicoletta Maxia | Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura |
| CN103143000B (zh) * | 2013-03-07 | 2014-11-05 | 安徽安科生物工程（集团）股份有限公司 | 一种重组人干扰素α2b制剂 |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| JP2014208669A (ja) * | 2014-06-17 | 2014-11-06 | 株式会社スリー・ディー・マトリックス | タンパク質の凝集抑制剤 |
| HUE069126T2 (hu) | 2014-12-03 | 2025-02-28 | Csl Behring Ag | Immunoglobulinokat tartalmazó megnövelt stabilitású gyógyszerészeti termék |
| AU2017276758A1 (en) | 2016-06-10 | 2018-11-08 | Boehringer Ingelheim International Gmbh | Combinations of Linagliptin and metformin |
| KR101943160B1 (ko) * | 2016-10-06 | 2019-01-30 | 에이비온 주식회사 | 인터페론 베타 변이체의 안정화 제제 |
| LT3672631T (lt) | 2017-08-22 | 2023-04-25 | Biogen Ma Inc. | Farmacinės kompozicijos, kurių sudėtyje yra antikūnų prieš beta amiloidą |
| KR102731889B1 (ko) * | 2019-07-18 | 2024-11-19 | 에이비온 주식회사 | 2당화된 인터페론-베타 단백질의 정제 방법 |
| CN110714051B (zh) * | 2019-11-20 | 2023-04-07 | 迈克生物股份有限公司 | 蛋白c活性测定试剂盒 |
| KR102593710B1 (ko) * | 2020-04-29 | 2023-10-25 | 에이비온 주식회사 | 이중 돌연변이를 가지는 인간 인터페론-베타 변이체 및 인간 인터페론-베타 변이체의 안정성을 향상시키는 방법 |
| CN114177273B (zh) * | 2021-11-29 | 2024-05-28 | 苏州人本药业有限公司 | 一种含有神经毒素的液体制剂及其制备方法 |
| JP2025501169A (ja) * | 2021-12-27 | 2025-01-17 | エナラーレ セラピューティクス インコーポレイテッド | 呼吸刺激薬非経口製剤 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57175125A (en) * | 1981-04-20 | 1982-10-28 | Wakunaga Yakuhin Kk | Preparation of beta-interferon |
| EP0082481B2 (en) * | 1981-12-23 | 1990-09-12 | Schering Corporation | Stabilised alpha-interferon formulations and their preparation |
| JPS60243028A (ja) * | 1984-04-28 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | インタ−フエロンの可溶化方法 |
| JPS63196268A (ja) * | 1987-02-10 | 1988-08-15 | Kanegafuchi Chem Ind Co Ltd | 無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法 |
| EP0284249A1 (en) * | 1987-03-13 | 1988-09-28 | Interferon Sciences, Inc. | Lyophilized lymphokine composition |
| DE3729863A1 (de) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
| US4895716A (en) * | 1987-06-09 | 1990-01-23 | Biogen, Inc. | Stabilized formulations of gamma interferons |
| JPH02124832A (ja) * | 1988-07-08 | 1990-05-14 | Toray Ind Inc | インターヘェロンβ組成物 |
| DE3939346A1 (de) * | 1989-11-29 | 1991-06-06 | Behringwerke Ag | Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide |
| IL109350A (en) * | 1993-05-12 | 2001-01-28 | Genentech Inc | Stable liquid compositions of gamma interferon |
| TW249202B (cs) * | 1993-08-13 | 1995-06-11 | Ciba Gerigy Corp | |
| US5545723A (en) * | 1994-03-15 | 1996-08-13 | Biogen Inc. | Muteins of IFN-β |
| EP0752880A4 (en) * | 1994-04-08 | 2000-08-09 | Brigham & Womens Hospital | TREATMENT OF AUTOIMMUNE DISEASES BY ORAL TOLERATION AND / OR INTERFERON OF TYPE I |
| IT1272252B (it) * | 1994-05-16 | 1997-06-16 | Applied Research Systems | Formulazioni liquide di interferone beta |
| TW426523B (en) * | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| CN1222315C (zh) * | 1996-12-24 | 2005-10-12 | 拜奥根有限公司 | 稳定的液体干扰素制剂 |
-
1997
- 1997-12-23 CN CNB971814996A patent/CN1222315C/zh not_active Expired - Lifetime
- 1997-12-23 IL IL13052497A patent/IL130524A/xx not_active IP Right Cessation
- 1997-12-23 SK SK858-99A patent/SK284989B6/sk not_active IP Right Cessation
- 1997-12-23 NZ NZ336548A patent/NZ336548A/en not_active IP Right Cessation
- 1997-12-23 TR TR1999/01968T patent/TR199901968T2/xx unknown
- 1997-12-23 CA CA2275890A patent/CA2275890C/en not_active Expired - Lifetime
- 1997-12-23 ES ES97952621T patent/ES2224290T5/es not_active Expired - Lifetime
- 1997-12-23 HU HU0000829A patent/HU224222B1/hu active IP Right Grant
- 1997-12-23 PT PT97952621T patent/PT948358E/pt unknown
- 1997-12-23 EP EP97952621A patent/EP0948358B2/en not_active Expired - Lifetime
- 1997-12-23 PL PL97334365A patent/PL193447B1/pl unknown
- 1997-12-23 JP JP52905698A patent/JP4878664B2/ja not_active Expired - Fee Related
- 1997-12-23 WO PCT/US1997/023817 patent/WO1998028007A1/en not_active Application Discontinuation
- 1997-12-23 DE DE69729880T patent/DE69729880T3/de not_active Expired - Lifetime
- 1997-12-23 AU AU56191/98A patent/AU738362B2/en not_active Expired
- 1997-12-23 BR BR9714434-7A patent/BR9714434A/pt active Search and Examination
- 1997-12-23 EE EEP199900313A patent/EE04223B1/xx unknown
- 1997-12-23 SI SI9730670T patent/SI0948358T2/sl unknown
- 1997-12-23 KR KR1019997005701A patent/KR20000069664A/ko not_active Ceased
- 1997-12-23 CN CN2005100915177A patent/CN1733296B/zh not_active Expired - Lifetime
- 1997-12-23 EE EEP200300127A patent/EE04266B1/xx unknown
- 1997-12-23 EA EA199900597A patent/EA002754B1/ru not_active IP Right Cessation
- 1997-12-23 CZ CZ0228299A patent/CZ300636B6/cs not_active IP Right Cessation
- 1997-12-23 AT AT97952621T patent/ATE270899T1/de active
- 1997-12-23 DK DK97952621.7T patent/DK0948358T4/da active
- 1997-12-23 KR KR1020077010020A patent/KR101042660B1/ko not_active Expired - Lifetime
-
1999
- 1999-06-21 IS IS5087A patent/IS2070B/xx unknown
- 1999-06-23 NO NO993121A patent/NO327844B1/no not_active IP Right Cessation
- 1999-06-23 MX MX2012000515A patent/MX337876B/es unknown
- 1999-07-19 BG BG103594A patent/BG65171B1/bg unknown
- 1999-07-19 BG BG109523A patent/BG65418B1/bg unknown
-
2001
- 2001-07-05 NZ NZ512792A patent/NZ512792A/xx not_active IP Right Cessation
-
2007
- 2007-05-18 JP JP2007133540A patent/JP2007204501A/ja not_active Withdrawn
-
2011
- 2011-01-07 JP JP2011002557A patent/JP5851695B2/ja not_active Expired - Lifetime
- 2011-10-04 JP JP2011220534A patent/JP2012006979A/ja not_active Withdrawn
-
2014
- 2014-02-25 JP JP2014033581A patent/JP2014098029A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE04223B1 (et) | Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid | |
| CA2113995A1 (en) | Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins | |
| IL95118A0 (en) | Polypeptide derivatives,their preparation and pharmaceutical compositions containing them | |
| CA2085750A1 (en) | Osteoinductive pharmaceutical formulations | |
| EP0222483A3 (en) | Use of gamma-linolenic acid and related compounds in the treatment of endometriosis | |
| CA2094027A1 (en) | Osteogenic peptides | |
| ATE56729T1 (de) | Protein mit zellwachstumsstimulierender wirkung, dessen zusammensetzung und verfahren zu seiner herstellung. | |
| TW364850B (en) | Nematocidal compositions | |
| AU4009789A (en) | Recombinant natural killer cell activator | |
| LTIP610A (en) | Inhibitors of cells proliferation, pharmaceutical composition and method for preparation of compounds | |
| ZA941198B (en) | Highly concentrated TCF pharmaceutical preparations | |
| AU3494093A (en) | S-lipophilic aliphatic carbonyl {n-mercaptoacyl-(amino acid or peptide)} compounds as antihypertensive agents | |
| EP0063328A3 (en) | Compositions containing secretin and method for preventing the adsorption of secretin | |
| Sebald et al. | Cooperation of mitochondrial and cytoplasmic protein synthesis in the formation of cytochrome c oxidase | |
| CA2153071A1 (en) | Derivatized calcitonins | |
| KR860003012A (ko) | (-)시스-1,2-에폭시프로필포스폰산과 아미노산과의 염을 함유하는 수용성 제약 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB4A | Valid patent at the end of a year |
Effective date: 20041231 |
|
| HC1A | Change of owner name | ||
| KB4A | Valid patent at the end of a year |
Effective date: 20051231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20061231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20071231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20101231 |